newsfilter
← Latest News
GlobeNewswire·

IO Biotech Reports 2024 Business Highlights

Preparations for submission of a Biologics License Application (BLA) for Cylembio® (imsapepimut and etimupepimut, adjuvanted) to FDA by year end 2025 remain on track. The trial completed enrollment in December 2023